|
|
|
| Effect of Magnesium Isoglycate Combined with Ademetionine Succinate on Liver Function and Prognosis after Interventional Therapy for Primary Liver Cancer |
| CHEN Hong-wei, YANG Sun-hu |
| General Surgery Department of the Ninth People's Hospital of Shanghai, Shanghai 201999 |
|
|
|
|
Abstract 【Objective】To explore the effect of magnesium isoglycate combined with ademetionine succinate on liver function and prognosis after interventional therapy for primary liver cancer.【Methods】One hundred and eighty patients with primary liver cancer who were treated in our hospital from August 2014 to may 2017 were selected as the study objects. According to the different schemes of liver protection after TACE, it was divided into two groups: group A (reduced glutathione + magnesium isoglycate injection) and group B (magnesium isoglycate + adenosylmethionine succinate). Serum ALT, AST, DBIL and TBIL levels were compared between the two groups. The adverse reactions of the two groups were observed to analyze the prognostic factors of patients with primary liver cancer.【Results】After treatment, the levels of ALT, AST, DBIL and TBIL in the two groups were significantly higher than those before treatment (P<0.05). The levels of ALT, AST, DBIL and TBIL in the group B were lower than those in the group A (P<0.05). The incidence of gastrointestinal reaction, leucopenia, hemoglobin reduction and thrombocytopenia in the group A were 26.44%, 25.29%, 20.69% and 2.30% respectively; the incidence of gastrointestinal reaction, leucopenia, hemoglobin reduction and thrombocytopenia in the group B were 24.73%, 20.43%, 16.13% and 2.15%, respectively. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The mean survival time of the group A was 27.40 (95% CI: 25.22~29.59) months, and that of the group B was 30.27 (95% CI: 28.40~32.14) months.There was significant difference between the two groups in the 3a survival time (P<0.05).Cox single factor and multi factor analysis showed that tumor number, vascular invasion and liver protection were closely related to the prognosis of patients with primary liver cancer.【Conclusion】Magnesium isoglycate combined with ademetionine succinate can improve the liver function and prognosis of patients with primary liver cancer after TACE treatment, which is worthy of clinical promotion.
|
|
Received: 19 May 2019
|
|
|
|
|
|
[1] Wang Z, Zhang G, Wu J,et al. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect[J].Drug Discov Ther,2013,7(4):137-143.
[2] Seki A, Kobayashi K, Narumiya S. Transcatheter Arterial Chemoembolization with Epirubicin-Loaded Superabsorbent Polymer Microspheres for 135 Hepatocellular Carcinoma Patients: Single-Center Experience[J].Cardiovasc Intervent Radiol,2011,34(3):557-565.
[3] 高慧涛,王美玲,陈小冰,等.复方甘草酸苷联合舒肝宁对原发性肝癌肝动脉灌注化疗栓塞术后保肝作用的临床观察[J].中国药物与临床,2013,13(11):1487-1488.
[4] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华消化外科杂志,2017,16(7):635-647.
[5] 何强.苦参素辅助治疗乙型病毒性肝炎相关原发性肝癌的临床观察[J].中国医院药学杂志,2014,34(22):1930-1933.
[6] Chen ZH, Zhang XP, Cai XR, et al. The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy[J].J Cancer,2018,9(19):3467-3478.
[7] Yu JI, Choi GS, Lim DH, et al. Treatment of Na ve HCC combined with segmental or subsegmental portal vein tumor thrombosis:liver resection versus TACE followed by radiotherapy[J].Anticancer Res,2018,38(8):4919-4925.
[8] Chen J, Zhang Y, Cai H, et al. Comparison of the effects of postoperative prophylactic transcatheter arterial chemoembolization (TACE) and transhepatic arterial infusion (TAI) after hepatectomy for primary liver cancer[J].J BUON,2018,23(3):629-634.
[9] 中华医学会感染病学分会,肝脏炎症及其防治专家共识专家委员会.肝脏炎症及其防治专家共识[J].中华肝脏病杂志,2014,22(2):94-103.
[10] 广东省抗癌协会肝癌专业委员会.肝癌多学科综合治疗团队建立--广东专家共识(1)[J].临床肝胆病杂志,2014,34(11):1112-1115.
[11] 武中林,吴勇超,杨超,等.原发性肝癌经导管肝动脉化疗栓塞术后应用不同保肝方案的效果比较研究[J].中国全科医学,2017,20(23):2862-2867,2874. |
|
|
|
2020, Vol. 37 
